The next D&T Committee meeting will be held September 13, 2017
HFS will be reviewing the following classes for the September meeting:
Diabetes DPP-4 Inhibitors
Diabetes GLP-1 Receptor Agonists
Diabetes SGLT2 Inhibitors
Diabetes Long Acting Insulin
Stimulants/ADHD Agents
All clinical and financial submissions for this meeting must be sent to the Department no later than 3pm CST on August 23, 2017. Any changes to drug status will become effective on or after October 1, 2017.